Menu Search
Equities

Divi's Laboratories Ltd

DIVISLAB:NSI

Divi's Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)6,022.00
  • Today's Change48.05 / 0.80%
  • Shares traded85.73k
  • 1 Year change+62.53%
  • Beta0.5376
Data delayed at least 15 minutes, as of Nov 22 2024 05:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy3
Outperform4
Hold5
Sell5
Strong Sell6

Share price forecast in INR

The 23 analysts offering 12 month price targets for Divi's Laboratories Ltd have a median target of 5,285.00, with a high estimate of 6,850.00 and a low estimate of 3,590.00. The median estimate represents a -11.53% decrease from the last price of 5,973.95.
High14.7%6,850.00
Med-11.5%5,285.00
Low-39.9%3,590.00

Dividends

In 2024, Divi's Laboratories Ltd reported a dividend of 30.00 INR, equaling last years dividend. The 19 analysts covering the company expect dividends of 28.09 INR for the upcoming fiscal year, a decrease of 6.36%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in INR

On Nov 09, 2024, Divi's Laboratories Ltd reported 2nd quarter 2025 earnings of 19.20 per share. This result was in line with the consensus of the 4 analysts following the company and exceeded last year's 2nd quarter results by 46.45%.
The next earnings announcement is expected on Feb 08, 2025.
Average growth rate+12.87%
Divi's Laboratories Ltd reported annual 2024 earnings of 60.27 per share on May 25, 2024.
Average growth rate+10.67%
More ▼

Revenue history & estimates in INR

Divi's Laboratories Limited had 2nd quarter 2025 revenues of 23.38bn. This bettered the 22.26bn consensus of the 13 analysts covering the company. This was 31.50% above the prior year's 2nd quarter results.
Average growth rate+5.92%
Divi's Laboratories Limited had revenues for the full year 2024 of 78.45bn. This was 1.00% above the prior year's results.
Average growth rate+11.36%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.